Dupilumab
Indication
Severe asthma with Type 2 inflammation
NICE TA751 - Dupilumab for treating severe asthma with type 2 inflammation
Red
Brand:
Nice TA:
751
Commissioning responsibility:
NHS England
PbR excluded:
Yes
BNF chapter:
Respiratory system
Background
1.1 Dupilumab as add-on maintenance therapy is recommended as an option for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over, despite maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment, only if:
- the dosage used is 400 mg initially and then 200 mg subcutaneously every other week
- the person has agreed to and follows an optimised standard treatment plan
- the person has a blood eosinophil count of 150 cells per microlitre or more and fractional exhaled nitric oxide of 25 parts per billion or more, and has had at least 4 or more exacerbations in the previous 12 months
- the person is not eligible for mepolizumab, reslizumab or benralizumab, or has asthma that has not responded adequately to these biological therapies
- the company provides dupilumab according to the commercial arrangement.